Data & Analytics
Judges praised Wunderman Health and GSK for their agility in reacting to dynamic information and creating segment-specific messaging for nasal spray allergy treatment Flonase.
A tracking poll conducted by the Kaiser Family Foundation also found that fewer Americans are seeing prescription drug ads compared to last year.
Mayo Clinic's CEO talks about how a trusted name in healthcare has evolved digitally and centered communications on its newsroom while retaining integrity.
Physicians are seeking beyond-the-pill services from drugmakers; Novartis debunks misconception that only smokers get lung cancer; pharma's access to docs declines
Discovering Meaningful Insights in Patient Journeys: Identifying Hidden Patterns Using Advanced AnalyticsSeptember 21, 2016
During this seminar, attendees will learn how advanced data analytics can be applied to gain a measurable competitive advantage.
In this webcast, TrialCard VP of analytic services Paul LeVine and senior analytic consultant Robert Leedom underscore how affordability programs provide the ideal venue for focusing on adherence issues.
In this sponsored podcast, MM&M's Larry Dobrow speaks with Robert Leedom, senior analytics consultant at TrialCard, and Paul LeVine, VP of analytic services for TrialCard, about how to reach patients by leveraging brand data.
A new government investigation found that most but not all prices for generic drugs dispensed by Medicare Part D fell from 2010 to 2015.
Physicians are seeking beyond-the-pill services from drugmakers, but few sales reps shares details with docs about these programs, a new report finds.
Jawbone data shows that people mentioning Pokémon Go in their comments have been walking 62.5% more than usual.
Mergers and acquisitions targeting digital and data capabilities increased 60% to $1 billion in the first half of 2016.
IBM to help analyze data about the spread of Zika; Grassley to investigate Part D program; Lilly CEO to retire
Spending on CME rose in 2015; the FDA approves Valeant's Relistor; the Justice Department aims to block insurer merger
Healthcare marketing is evolving more rapidly than ever before — and not surprisingly, the demand for smarter media campaign measurement is increasing as a result.
A new analysis suggests that $20 industry-sponsored meals may sway docs' prescribing habits.
The ability to pair data with a story or a human emotion is often easier for women.
Despite the increasing importance of the CIO post, top technology professionals still find it hard to break into the uppermost ranks at life-sciences companies.
Only 55% of the surveyed pharmaceutical executives said they are adopting digital as a key strategy in R&D.
BIO report finds success rate in Phase-I is 10%; Dunsire departs Forum after failed trials; the FDA issues two warning letters
Two recent polls paint a complicated picture of the public's opinion of the pharma industry.
Keytruda's survival benefit is reinforced by new study; drugmakers reference patient-assistance programs in debate over drug prices; China cuts drug prices
A 69% majority of healthcare organizations said they believe their industry is more vulnerable to data breaches than other business sectors.
Learn more about the top therapeutic categories by sales, top companies by revenue, top drugs by sales, and more.
"Social can enable a better starting point to yield better questions and thus make surveys less in number yet greater in value."
The move away from a fee-for-service reimbursement model and the arrival of promising new technology have created demand for big data in healthcare.
2015 marks the second straight double digit increase in spend, which was driven by recent launches and specialty brands.
Analyst survey says docs want outcomes benefit from PCSK9s; Allergan licenses early-stage Alzheimer's drugs; Pfizer and IBM partner in Parkinson's disease
The results of a failed trial for Lilly's CEPT inhibitor has analysts saying there is little hope for Merck's drug in the same class.
Given the value of its data and its relatively backward security measures, the healthcare industry has become a prime target for hackers. But industry experts say changes are afoot.
Time is everything, yet no one has enough of it. But especially in healthcare marketing, time and timing win customers.
- Guidemark Health merges with three companies to form new agency
- Five things for pharma marketers to know: Monday, October 17, 2016
- Five things for pharma marketers to know: Thursday, October 20, 2016
- Five things for pharma marketers to know: Tuesday, October 18, 2016
- Five things for pharma marketers to know: Wednesday, October 19, 2016
- Merck educates doctors about biosimilars, long before it will sell one in the U.S.
- 4 trends with the potential to change behavior in the patient journey
- 2016 Pharma Report: All the data in one place
- What do physicians think about biosimilars?
- Novartis considers new sales model for experimental cancer therapy
- If Roche's Ocrevus is approved, the already competitive MS market will gain another player
- Top 25 neurology products, based on 2016 sales forecasts
- New science drives biopharma interest in neurological conditions
- J&J exec calls California pricing measure 'misguided'
- Five things for pharma marketers to know: Monday, October 24, 2016